Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24803922 | 0.90 | LMNA (0.65) | POLBPTBP1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL24804696 | 0.87 | LMNA (0.72) | POLBPTBP1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL24805003 | 0.87 | PTBP1 (0.63) | POLBPTBP1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL24805066 | 0.87 | KMT2A (0.64) | POLBPTBP1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL24804598 | 0.85 | POLB (0.66) | POLBPTBP1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL24803877 | 0.84 | PTBP1 (0.70) | POLBPTBP1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL24803894 | 0.83 | LMNA (0.80) | POLBPTBP1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL24804002 | 0.83 | PTBP1 (0.71) | POLBPTBP1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL24803805 | 0.82 | PTBP1 (0.68) | POLBPTBP1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL24803791 | 0.82 | PTBP1 (0.65) | POLBPTBP1SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411419-A1 | SMALL MOLECULE MODULATORS OF MHC-I | RETROVIROX, INC. | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411419-A1 | SMALL MOLECULE MODULATORS OF MHC-I | CD74, HLA-DRB1, MICA | POLB 2268/4885PTBP1 2774/4885SMN1; SMN2 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.